The article you requested is
Female Reproductive Life Cycle and Hormones: Methodology to Improve Clinical Trials <span class="cme">[Commentary]</span>
Marlene P. Freeman, MD; Rosemary Walker, BA; Thomas P. Laughren, MD; Karen K. Miller ,MD; and Maurizio Fava, MD
J Clin Psychiatry 2013;74(10):1018-1021
10.4088/JCP.13com08742
© Copyright 2017 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
-
-
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
-
Subscribe
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
-
-
Activate
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
-
Sign in
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
-
Click here to login.
-
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Article Abstract
Because this piece does not have an abstract, wehave provided for your benefit the first 3 sentences of the fulltext.
In clinical trials, there are 2 competing ethical priorities regarding the participation of women. One is that women of childbearing potential could become pregnant during a trial, raising concern over fetal exposure to an agent of unknown reproductive safety. The other is the need for development of treatments specific to subpopulations of patients in order to better inform care.